Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy

Summary

Up to nine subjects who have participated in the earlier LX101 clinical study, and who meet all study eligibility criteria, will receive LX101 administration in the previously uninjected, contralateral eye to evaluate the safety of bilateral, sequential subretinal administration of LX101.

Timeline

Start

2023-09-12

Primary completion

2025-02-06

Completion

2029-03

Drugs

Indications